DOCSLIB.ORG

Pamidronate 1101 Pamidronate Along with Renal Function

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pamidronate 1101 Pamidronate Along with Renal Function Ipriflavone/Pamidronate 1101 Pamidronate along with renal function. Patients should be warned women with osteogenesis imperfecta given intravenous pamid- against driving or operating machinery after treatment ronate before conception. One infant had transient asymptomatic ATC — M05BA03. if somnolence or dizziness occur. hypocalcaemia, and one had bilateral talipes equinovarus (a con- ATC Vet — QM05BA03. genital deformity in which the foot turns downwards and in- Effects on the ears. Ototoxicity, manifest as tinnitus and sud- wards). No other skeletal abnormalities were noted. The authors den hearing loss, has been reported1 in 2 patients given both in- advised monitoring of neonatal calcium concentrations in infants Pamidronic Acid (BAN, rINN) travenous and oral pamidronate for pre-existing otosclerosis.1 A born to mothers treated with pamidronate.1 In another report of 3 Acide Pamidronique; Ácido pamidrónico; Acidum Pamidroni- patient given 5 pamidronate infusions for Paget’s disease devel- women given long-term pamidronate before conception, 4 cum; Aminohydroxypropylidenebisphosphonate; APD; Pamid- oped tinnitus, vertigo, and hearing loss; the latter two symptoms healthy infants were born with no evidence of biochemical or 2 2 ronihappo; Pamidronsyra. 3-Amino-1-hydroxypropylidene- resolved over 9 months, but tinnitus persisted. skeletal abnormalities. bis(phosphonic acid). 1. Boumans LJJM, Poublon RML. The detrimental effect of amino- 1. Munns CFJ, et al. Maternal and fetal outcome after long-term hydroxypropylidene bisphosphonate (APD) in otospongiosis. pamidronate treatment before conception: a report of two cases. Памидроновая Кислота Eur Arch Otorhinolaryngol 1991; 248: 218–21. J Bone Miner Res 2004; 19: 1742–5. C H NO P = 235.1. 2. Reid IR, et al. Ototoxicity associated with intravenous bisphos- 2. Chan B, Zacharin M. Maternal and infant outcome after pamid- 3 11 7 2 phonate administration. Calcif Tissue Int 1995; 56: 584–5. ronate treatment of polyostotic fibrous dysplasia and osteogene- CAS — 40391-99-9. sis imperfecta before conception: a report of four cases. J Clin ATC — M05BA03. Effect on electrolytes. Pamidronate has precipitated severe Endocrinol Metab 2006; 91: 2017–20. hypocalcaemia, resulting in tetany and paraesthesia, in 2 pa- ATC Vet — QM05BA03. tients. In each case, other conditions interfered with the expected 1 Interactions compensatory physiological response to the hypocalcaemia. As for the bisphosphonates in general, p.1091. 1. Peter R, et al. Severe hypocalcaemia after being given intrave- NH2 nous bisphosphonate. BMJ 2004; 328: 335–6. Effects on the eyes. For reports of ocular effects with the bis- Pharmacokinetics O phosphonates, including pamidronate, see under Bisphospho- Plasma concentrations of pamidronate rise rapidly af- nates, p.1090. ter the start of an intravenous infusion; the apparent HO P OH Effects on the gastrointestinal tract. The tolerability of pa- plasma half-life is 0.8 hours. Plasma protein binding is HO P O midronate given orally may depend to some extent on the partic- about 54%. Pamidronate is not metabolised, and about HO ular formulation. Gastrointestinal disturbances (in 21.8%) and 20 to 55% of the dose is excreted in the urine un- OH haematological abnormalities (in 9.4%) were the main adverse changed within 72 hours; the remainder is mainly se- effects associated with oral pamidronate in an open study of eld- erly patients.1 Oesophagitis, noted earlier2 in 4 of 49 patients giv- questered to bone and only very slowly eliminated. Re- 1 Pamidronate Disodium (USAN, rINNM) en a different formulation, was not reported in this study. nal clearance is slower in patients with severe renal 1. Spivacow FR, et al. Tolerability of oral pamidronate in elderly impairment and infusion rates may need to be reduced Aminohydroxypropylidenebisphosphonate Disodium; CGP- patients with osteoporosis and other metabolic bone diseases. 23339A; CGP-23339AE; Dinatrii pamidronas pentahydricus; Di- Curr Ther Res 1996; 57: 123–30. (see below). natriumpamidronaattipentahydraatti; Dinatrium-pamidronát 2. Lufkin EG, et al. Pamidronate: an unrecognised problem in gas- Like all bisphosphonates, oral pamidronate is poorly pentahydrát; Disodium Aminohydroxypropylidenediphospho- trointestinal tolerability. Osteoporosis Int 1994; 4: 320–2. absorbed from the gastrointestinal tract; bioavailability nate; Disodium Pamidronate (BANM); Disodu pamidronian pię- Effects on the kidneys. Like other bisphosphonates (see is about 1 to 3%. ciowodny; Disodyum Pamidronat; Pamidronaattidinatrium; Pa- p.1091), pamidronate may cause adverse renal effects. UK li- censed product information notes that there have been isolated midronas Dinatricum; Pamidronatdinatrium; Pamidronatdinatri- Uses and Administration umpentahydrat; Pamidronate Disodique; Pamidronate disodique cases of haematuria, acute renal failure, and deterioration of pre- existing renal disease. Renal function should be monitored dur- Pamidronate is an aminobisphosphonate with general pentahydraté; Pamidronato disódico; Pamidronatum Dinatricum. ing long-term pamidronate therapy, especially in patients with properties similar to those of the other bisphosphonates Disodium 3-amino-1-hydroxypropylidenebisphosphonate pen- pre-existing renal disease or a predisposition to renal impair- tahydrate. (p.1091). It inhibits bone resorption, but appears to ment. Longer infusion times may reduce the risk of renal toxicity, have less effect on bone mineralisation than etidronate Динатрий Памидронат and various infusion rates have been recommended, see Uses and Administration, below. at comparable doses. C3H9NNa2O7P2,5H2O = 369.1. CAS — 109552-15-0 (pamidronate disodium pentahy- Effects on mental state. Palpitations, followed by visual hal- Pamidronate is used as an adjunct in the treatment of drate); 57248-88-1 (anhydrous pamidronate disodium). lucinations, suicidal ideation, and clinical depression were re- severe hypercalcaemia, especially when associated ATC — M05BA03. ported in an elderly man after a single infusion of pamidronate with malignancy. It is also used in the treatment of os- ATC Vet — QM05BA03. for Paget’s disease; he had no previous psychiatric history. Treat- teolytic lesions and bone pain in multiple myeloma or ment with thioridazine reduced the frequency and effect of the In Eur. (see p.vii) and US. Pharmacopoeias. hallucinations.1 bone metastases associated with breast cancer. It may Ph. Eur. 6.2 (Pamidronate Disodium Pentahydrate). A white or also be of benefit in bone disorders associated with ex- almost white, crystalline powder. Soluble in water; practically 1. Foley-Nolan D, et al. Pamidronate associated hallucinations. Ann Rheum Dis 1992; 51: 927–8. cessive bone resorption, including Paget’s disease of insoluble in dichloromethane. It is sparingly soluble in dilute mineral acids and dissolves in dilute alkaline solutions. A 1.0% Effects on the musculoskeletal system. Although bone. solution in water has a pH of 7.8 to 8.8. pamidronate appears to be a less potent inhibitor of bone miner- Pamidronate disodium is given by slow intravenous in- USP 31 (Pamidronate Disodium). A white crystalline powder. alisation than etidronate, mineralisation defects have been re- fusion. UK licensed product information recommends Soluble in water and in 2N sodium hydroxide; sparingly soluble ported in patients with Paget’s disease of bone receiving pamid- 1 infusion at a rate not exceeding 60 mg/hour (or not ex- 0.1N acetic acid and in 0.1N hydrochloric acid; practically insol- ronate. The resultant osteomalacia was not associated with any adverse clinical effects. Pamidronate-induced osteopetrosis has ceeding 20 mg/hour in patients with established or sus- uble in organic solvents. pH of a 1% solution in water is between 2 7.8 and 8.8. Store in airtight containers at a temperature not ex- also been reported. Acute pseudogout arthritis in a woman treat- pected renal impairment) and at a concentration not ex- ceeding 30°. ed with pamidronate for acute hypercalcaemia was possibly due ceeding 60 mg per 250 mL of infusion solution to deposition of calcium in the joints.3 Severe bone pain occurred in more patients than expected when pamidronate was used for (sodium chloride 0.9% or glucose 5%). In the USA, the Adverse Effects, Treatment, and Precau- treatment of low bone density in cystic fibrosis;4 an increase in recommended concentration of infusion and rate vary tions proinflammatory cytokines was postulated as a mechanism for depending on the indication. 5 As for the bisphosphonates in general, p.1089. this effect. In hypercalcaemia of malignancy pamidronate diso- Osteonecrosis of the jaw has been reported after the use of bis- Fever and flu-like symptoms (sometimes accompanied phosphonates, including pamidronate (see Effects on the Musc- dium is given by slow intravenous infusion in a total by malaise, rigors, fatigue, and flushes) are common uloskeletal System, under Adverse Effects of Bisphosphonates, dose of 15 to 90 mg according to the initial plasma- during intravenous infusion of pamidronate but gener- p.1091). calcium concentration. In the UK, the total dose is giv- ally resolve spontaneously. Pamidronate should not be 1. Adamson BB, et al. Mineralisation defects with pamidronate en as a single infusion or in divided doses over 2 to 4 therapy for Paget’s disease. Lancet 1993; 342: 1459–60. given by bolus injection, as severe local reactions and 2. Whyte MP, et al. Bisphosphonate-induced osteopetrosis. N Engl days. In the USA, the total dose is given as a single
Load more

Recommended publications
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • Protocol Supplementary
    Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf.
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • Re-Evaluated Data of Dissociation Constants of Alendronic, Pamidronic and Olpadronic Acids
    Cent. Eur. J. Chem. • 7(1) • 2009 • 8-13 DOI: 10.2478/s11532-008-0099-z Central European Journal of Chemistry Re-evaluated data of dissociation constants of alendronic, pamidronic and olpadronic acids Invited Paper Alexander P. Boichenko1, Vadim V. Markov1, Hoan Le Kong1, Anna G. Matveeva2, Lidia P. Loginova1* 1Department of Chemical Metrology, Kharkov V.N. Karazin National University, 61077 Kharkov, Ukraine. 2A.N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 119991 Moscow, Russian Federation Received 01 April 2008; Accepted 23 October 2008 Abstract: The dissociation constants of (4-amino-1-hydroxybutylidene)bisphosphonic (alendronic) acid, (3-(dimethylamino)-1- hydroxypropylidene)bisphosphonic (olpadronic) acid and (3-amino-1-hydroxypropylidene)bisphosphonic (pamidronic) acid were obtained in aqueous solutions (0.10 М КСl) and micellar solutions of cetylpyridinium chloride (0.10 М CPC) at 25.0°C. With the exception of the third dissociation constant of alendronic acid, the dissociation constants of alendronic, olpadronic and pamidronic acids in aqueous solutions matched literature data. The possibility of sodium alendronate determination by acid-base titration by NaOH solution was theoretically grounded on the basis of re-evaluated data of alendronic acid dissociation constants. Keywords: Alendronate • Olpadronate, pamidronate, dissociation constant • Micellar media effect © Versita Warsaw and Springer-Verlag Berlin Heidelberg. 1. Introduction spectrometric [12], refractive index [13] and Sodium salts of (4-amino-1-hydroxybutylidene) conductometric [14] detection have been proposed. bisphosphonic (alendronic) acid, (3-(dimethylamino)- The anion-exchange chromatography with refractive 1-hydroxypropylidene)bisphosphonic (olpadronic) acid index detection is recommended by British and (3-amino-1-hydroxypropylidene)bisphosphonic Pharmacopoeia for the determination of sodium (pamidronic) acid are successfully used for the medical alendronate [15].
    [Show full text]
  • Phvwp Class Review Bisphosphonates and Osteonecrosis of the Jaw (Alendronic Acid, Clodronic Acid, Etidronic Acid, Ibandronic
    PhVWP Class Review Bisphosphonates and osteonecrosis of the jaw (alendronic acid, clodronic acid, etidronic acid, ibandronic acid, neridronic acid, pamidronic acid, risedronic acid, tiludronic acid, zoledronic acid), SPC wording agreed by the PhVWP in February 2006 Section 4.4 Pamidronic acid and zoledronic acid: “Osteonecrosis of the jaw has been reported in patients with cancer receiving treatment regimens including bisphosphonates. Many of these patients were also receiving chemotherapy and corticosteroids. The majority of reported cases have been associated with dental procedures such as tooth extraction. Many had signs of local infection including osteomyelitis. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g. cancer, chemotherapy, radiotherapy, corticosteroids, poor oral hygiene). While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.” Remaining bisphosphonates: “Osteonecrosis of the jaw, generally associated with tooth extraction and/or local infection (including osteomyelits) has been reported in patients with cancer receiving treatment regimens including primarily intravenously administered bisphophonates. Many of these patients were also receiving chemotherapy and corticosteroids. Osteonecrosis of the jaw has also been reported in patients with osteoporosis receiving oral bisphophonates. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with concomitant risk factors (e.g.
    [Show full text]
  • Best Practice & Research Clinical Rheumatology
    Best Practice & Research Clinical Rheumatology 24 (2010) 489e496 Contents lists available at ScienceDirect Best Practice & Research Clinical Rheumatology journal homepage: www.elsevierhealth.com/berh 5 Novel targets in bone and cartilage Christian Beyer, Georg Schett* Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany Keywords: The spectrum of arthritis ranges from erosive (e.g., rheumatoid bone arthritis) to ossifying disease with formation of new bone (e.g., anky- cartilage: FGF-18 losing spondylitis and osteoarthritis). The molecular basis for these hedgehog different patterns of arthritis had long been unclear. In the last few RANKL years, however, characterisation of catabolic and anabolic molecular sclerostin pathways in different forms of arthritis led to a better understanding of targets joint remodelling and revealed novel therapeutic targets. Wnt Recent findings show that catabolic and anabolic molecular pathways govern bone and cartilage remodelling in healthy and arthritic joints. The predominance of catabolic molecular pathways (e.g., receptor activator of nuclear factor-kB ligand (RANKL)/RANK and cathepsin K) causes erosive disease whereas anabolic signal- ling (e.g., Wnt and fibroblast growth factor (FGF)18) favours the formation of new bone including bony spurs and subchondral sclerosis. Other pathways may have a dual function in arthritis (e.g., hedgehog) leading to either catabolic or anabolic joint remodelling dependent on other factors. Key mediators within these signalling pathways may serve as novel targets for treating pathological remodelling of bone and cartilage in arthritis. Molecular pathways govern remodelling processes of bone and cartilage in arthritic joints. Future therapies will likely target the pathologic activity of these molecular pathways to specifically block either catabolic or anabolic joint remodelling in arthritis.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Fulvestrant Sponsor
    CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 021344Orig1s026 Trade Name: Faslodex Injection Generic Name: fulvestrant Sponsor: AstraZeneca Pharmaceuticals LP Approval Date: 03/02/2016 Indications: FASLODEX is an estrogen receptor antagonist indicated for the: • Treatment of hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. • Treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 021344Orig1s026 CONTENTS Reviews / Information Included in this NDA Review. Approval Letter X Other Action Letters Labeling X Summary Review Officer/Employee List X Office Director Memo X Cross Discipline Team Leader Review Medical Review(s) X Chemistry Review(s) X Environmental Assessment Pharmacology Review(s) Statistical Review(s) Microbiology Review(s) Clinical Pharmacology/Biopharmaceutics Review(s) X Risk Assessment and Risk Mitigation Review(s) Proprietary Name Review(s) Other Review(s) X Administrative/Correspondence Document(s) X CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 021344Orig1s026 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 021344/S-026 SUPPLEMENT APPROVAL AstraZeneca Pharmaceuticals LP Attention: Elinore Mercer, PhD Director Global Regulatory Affairs One MedImmune Way Gaithersburg, MD 20878 Dear Dr. Mercer: Please refer to your Supplemental New Drug Application (sNDA) dated November 17, 2015, received November 17, 201, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Faslodex® Injection (fulvestrant) Solution for Injection 250 mg/5 mL.
    [Show full text]
  • Effects of Teriparatide and Bisphosphonate on Spinal Fusion Procedure
    Effects of Teriparatide and Bisphosphonate on Spinal Fusion Procedure: A systematic review and network meta-analysis (Supplementary) Index of Supplementary Supplementary File 1. Database and search strategy Supplementary File 2. Risk of bias Supplementary File 3. Forest plot of fusion rate Supplementary File 4. Cumulative probability and SUCRA of fusion rate Supplementary File 5. Inconsistency test for network meta-analysis of fusion rate Supplementary File 6. Publication bias in network meta-analysis of fusion rate Supplementary File 7. Forest plot of ODI Supplementary File 8. Cumulative probability and SUCRA of ODI Supplementary File 9. Inconsistency test for network meta-analysis of ODI Supplementary File 10. Publication bias in network meta-analysis of ODI Supplementary File 11. Forest plot of adverse event Supplementary File 12. Cumulative probability and SUCRA of adverse event Supplementary File 13. Inconsistency test for network meta-analysis of adverse event Supplementary File 14. Publication bias in network meta-analysis of adverse event Supplementary 1 Database and search strategy Supplementary 1 Database and search strategy Database Search strategy #1. terrosu #2. forteo #3. teriparatide #4. parathyroid hormone #5. PTh #6. #1 OR #2 OR #3 OR #4 OR #5 #7. bonviva #8. alendronate #9. fosamax #10. olpadronate #11. neridronate #12. nericia #13. pamidronate #14. aredia #15. APD #16. zometa #17. avlasta #18. risedronate Primary #19. actonel search #20. boneva strategy #21. bisphosphonate #22. ibandronic #23. disambiguation #24. zoledronate #25. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 #26.
    [Show full text]
  • Prolonged Zoledronic Acid-Induced Hypocalcemia in Hypercalcemia of Malignancy
    CaseCommunity Report Report Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy Shraddha Narechania, MD,a Nirosshan Tiruchelvam, MD,a Chetan Lokhande, MD,b Gaurav Kistangari, MD,c and Hamed Daw, MDd aDepartment of Internal Medicine, bOutcomes Research, cDepartment of Hospital Medicine, and dDepartment of Hematology and Oncology, Fairview Hospital, Cleveland, Ohio oledronic acid is a parenteral long-acting value, <2 pmol/L), PTH of 10 pg/ml (normal range, bisphosphonate that has been shown to 15-65 pg/ml), creatinine of 1.1 mg/dL, and creati- Zbe more efective than other bisphospho- nine clearance of approximately 65 ml/min (normal nates in treating hypercalcemia of malignancy. It is range, 88-128 ml/min). Testing for her vitamin D important to be aware of its ability to induce pro- level was not done. longed and severe hypocalcemia (hypoCa) follow- Te patient received treatment with intravenous ing administration, which can be difcult to con- (IV) fuids, calcitonin, and a single 3.3-mg dose of trol despite aggressive calcium replacement. We IV zoledronic acid. After 6 days of treatment, her report on a patient with metastatic breast cancer calcium levels decreased to 12.1 mg/dL, and she was who presented with severe symptomatic hypoCa discharged home. She received her frst session of after receiving zoledronic acid for hypercalcemia of palliative chemotherapy a week after her discharge. malignancy. Two weeks after the zoledronic acid treatment, the patient presented to the hospital with diarrhea as Case presentation and summary well as tingling and numbness all over the body. A A 51-year-old woman was diagnosed with right- physical examination of the patient was remarkable sided breast cancer in 2012 for which she under- for carpopedal spasm of her upper extremities.
    [Show full text]
  • Guideline for the Management of Osteoporosis in Primary Care
    Guideline for the management of osteoporosis in primary care This guideline has been prepared and approved for use within County Durham & Darlington Clinical Commissioning Groups This guideline is not exhaustive and does not override the individual responsibility of health professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. This guideline should be used in conjunction with the following guidelines: NICE TA160 NICE TA161 NICE TA204 NICE CG146 NICE TA464 NOGG Osteoporosis clinical guideline for prevention and treatment SIGN 142 Full details of contra-indications and cautions for individual drugs are available in the BNF or in the Summary of Product Characteristics (available in the Electronic Medicines Compendium) www.emc.medicines.org.uk Version Number 2.0 November 2018 Date of County Durham and Darlington APC 01.11.2018 Approval Review Due November 2020 1 Fracture Risk Assessment Algorithm 2 Fracture Risk Assessment/ Osteoporosis Treatment Threshold – Additional Information Do not routinely assess fracture risk in patients aged under 50 years unless major risk factors present because they are unlikely to be at high risk NICE CG146 gives these major risk factors as; current of frequent recent use of oral or systemic glucocorticoids, untreated premature menopause or previous fragility fracture and these patients must have a risk assessment carried out. Quantifying the risk of fracture. Fracture risk assessment should be carried out,
    [Show full text]
  • Extreme Hypercalcaemia Caused by Immobilisation Due to Acute Spinal Cord Injury Jesse Marc Tettero,1 Elmer Van Eeghen,2 Albertus Jozef Kooter2
    Case report BMJ Case Rep: first published as 10.1136/bcr-2020-241386 on 2 June 2021. Downloaded from Extreme hypercalcaemia caused by immobilisation due to acute spinal cord injury Jesse Marc Tettero,1 Elmer van Eeghen,2 Albertus Jozef Kooter2 1Hematology, Amsterdam UMC SUMMARY pulse rate of 88 beats/min and a blood pressure of Location VUmc, Amsterdam, The Hypercalcaemia due to immobilisation is an uncommon 142/87 mm Hg. His ECG showed shortening of the Netherlands QT interval. Further diagnostics for a malignancy 2 diagnosis and requires extensive evaluation to rule out Internal Medicine, Amsterdam common causes of hypercalcaemia such as primary showed absence of M-protein and free light chains, UMC Location VUmc, hyperparathyroidism and malignancy. furthermore a positron emission tomography- CT Amsterdam, The Netherlands We report an unusual case of profound hypercalcaemia scan showed no bone lesions. Correspondence to due to immobilisation in a young man due to acute Dr Albertus Jozef Kooter; spinal cord ischaemia, leading to paraplegia. Other DIFFERENTIAL DIAGNOSIS JKooter@ amsterdamumc. nl causes of hypercalcaemia were ruled out and elevated Blood tests ruled out most causes of hypercal- bone turnover markers supported our hypothesis. caemia: primary hyperparathyroidism, granuloma- Accepted 5 May 2021 Conventional treatment with intravenous fluids, tous disease (normal 1.25 (OH)2- vitD) and tumour bisphosphonates and diuretics was insufficient. related. The patient had not consumed exces- Subcutaneous calcitonin lowered the plasma calcium sive amounts of calcium. Total parenteral nutri- acutely and was continued for 8 weeks. Subsequent tion is associated with hypercalcaemia, but only normocalcaemia was sustained for 2 years.
    [Show full text]